Form 4: Esperion Therapeutics CFO Benjamin Halladay Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 11 shares of common stock on February 19, 2025, at a price of $1.86 per share to satisfy tax obligations related to vested restricted stock units.
Summary
- On February 19, 2025, Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc., sold 11 shares of common stock.
- The shares were sold at a price of $1.86 per share.
- The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Halladay directly owns 240,671 shares of Esperion Therapeutics common stock.
- Halladay has granted Sheldon Koenig and Benjamin Looker power of attorney to execute SEC filings on his behalf.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, and has neutral sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency when company insiders trade their company's stock. This filing indicates that the CFO sold a small number of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 2022-11-16 | Date of execution of the Limited Power of Attorney. |
| 2025-02-19 | Date of the stock sale transaction. |
| 2025-02-20 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.